Imara

Imara Inc. has been dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious diseases.

News

Speech bubble

Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia

Imara Reports Full Year 2021 Financial Results and Business Highlights

TwitterLinkedIn

Imara, Inc.
116 Huntington Ave.
6th Floor
Boston, MA 02116
T: 617-206-2020
E: info@imaratx.com

Privacy Policy
Terms of Use
© 2021 Imara, Inc.

You are now leaving Imaratx.com

Links to sites outside of Imaratx.com are provided as a resource to the viewer. Imara is not responsible for and has no control over the content of linked sites.

No, I want to stay on Imaratx.com Yes, please proceed to the other site